NAD⁺ precursor — enters cells via ENT transporters, phosphorylated to NMN by NRK1/2, then adenylated to NAD⁺ by NMNAT. Smaller than NMN (no phosphate) so better cell entry. Raises whole-blood NAD⁺ ~40–60% at 300 mg/d in published RCTs.
Half-Life & Elimination Curve (PO: 1h)
Plasma (PO)t½ Decay (1h)
0×t½0h100%(1.36 mg/L)
1×t½1h50%(0.68 mg/L)
2×t½2h25%(0.34 mg/L)
3×t½3h12.5%(0.17 mg/L)
4×t½4h6.3%(85 µg/L)
5×t½5h3.1%(42.5 µg/L)
Elimination t½1h (PO)
Rate Constant (ke)0.693 h⁻¹
Time to Peak (Tmax)49m
Est. Peak (Cmax)1.36 mg/L
Clearance (CL)24.3 L/h
97% Washout (5×t½)5h
Dosing Guidelines
Oral (PO): Typical 167 mg (Range: 100–300 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 50% · Volume of Distribution (Vd): 35 L · Absorption (ka): 2 h⁻¹ (t½ka ≈ 21m) [PMID 27721479]